Vical Incorporated
Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
October 16, 2017 17:30 ET | Vical Incorporated
SAN DIEGO, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended September 30, 2017, before the...
Vical Incorporated
Vical to Provide Company Update at BIO Investor Forum Conference
October 13, 2017 16:05 ET | Vical Incorporated
SAN DIEGO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at...
Vical Incorporated
Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
October 10, 2017 06:30 ET | Vical Incorporated
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the last patient completed their final assessment during the one year follow-up period in the...
Vical Incorporated
Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
October 02, 2017 16:15 ET | Vical Incorporated
Vical plans to initiate Phase 2 trial of VL-2397 for the treatment of invasive aspergillosis in 4Q 2017 Management to host conference call on October 3rd at 12:00 pm ET to discuss the Phase 2 trial...
Vical Incorporated
Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
September 28, 2017 06:00 ET | Vical Incorporated
SAN DIEGO, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present a poster on its antifungal VL-2397 development program at the Infectious...
Vical Incorporated
Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 06, 2017 15:00 ET | Vical Incorporated
SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...
Vical Incorporated
Vical Reports Second Quarter 2017 Financial and Operational Results
August 08, 2017 06:30 ET | Vical Incorporated
SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2017. Net loss for the second quarter of 2017 was...
Vical Incorporated
Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
August 01, 2017 16:05 ET | Vical Incorporated
SAN DIEGO, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended June 30, 2017, before the...
Vical Incorporated
Vical to Provide Company Update at the 2017 BIO International Convention
June 15, 2017 16:05 ET | Vical Incorporated
SAN DIEGO, June 15, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will provide an overview of its technologies, development programs, and outlook at 4:15...
Vical Incorporated
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
June 05, 2017 06:30 ET | Vical Incorporated
VL-2397 appeared safe and well-tolerated with favorable pharmokinetic profile in healthy subjectsPhase 2 initiation is planned for the fourth quarter of 2017 SAN DIEGO, June 05, 2017 (GLOBE...